Apricus Biosciences

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has initiated a Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus recently completed enrollment in a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon. Apricus’ lead commercial product, Vitaros®, for the treatment of ED, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus’ marketing partners for Vitaros include Mylan NV, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus’ second-generation room temperature Vitaros is under development. Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the Nasdaq Capital Market under the ticker symbol APRI.
Company Growth (employees)
San Diego, US
Size (employees)
24 (est)
Apricus Biosciences is headquartered in San Diego, US

Apricus Biosciences Office Locations

Apricus Biosciences has office in San Diego
San Diego, US

Apricus Biosciences Metrics

Apricus Biosciences Summary

Market capitalization

$16.9 m

Closing share price

Apricus Biosciences's current market capitalization is $16.9 m.

Apricus Biosciences Financials

Apricus Biosciences's revenue is $2.5 m in FY, 2013 which is a 72.9% decrease from the previous period.
FY, 2013FY, 2014FY, 2015Y, 2016


$2.5 m$9.3 m$4.8 m$5.8 m

Revenue growth, %


Gross profit

($120 k)$8.3 m$3.9 m

Operating expense total

$17.2 m$30.9 m$25.3 m


($17.4 m)($22.6 m)($21.4 m)

Net Income

($16.9 m)($21.8 m)($19 m)

Operating cash flow

$6.3 m($10 m)($7.5 m)

Apricus Biosciences Market Value History

We estimate that Apricus Biosciences's current employees are approximately 46% female and 54% male.

Apricus Biosciences Online Presence

Apricus Biosciences News

Apricus Biosciences Company Life

You may also be interested in